HEALTH

C&D enters personal lubricant market, seeking to make Trojan intimacy health ‘mega-brand’

BY Michael Johnsen

NEW YORK — Trojan is about to enter the personal lubricant business, Jim Craigie, chairman and CEO for Church & Dwight, told analysts last week at the 2013 Consumer Analyst Group of New York Conference. 

"Trojan, finally, is entering the sexual lubricant category with a brand called Crazy Sexy Feel, under the Trojan brand name," Craigie said. "We hope to do this category, what the AXE brand did to the deodorant category."

C&D will be introducing three SKUs and will be sampling heavily to help drive share, Craigie said. "Big category, $250 million in sales," Craigie said. "Actually been a little soft or stagnant the last few years, because of a lack of innovation. We’re going to bring it to the category." Craigie noted that while condom use declines as people age, personal lubricant and personal massager use remains high over the course of a person’s lifespan. "This is all part of our strategy to turn Trojan into our next megabrand," he said. 

C&D is looking to become the No. 1 brand across three intimacy health segments, Craigie said. That includes the condom category, a $500 million category of which Trojan has a 66% dollar share; the personal massager category, about a $300 million category; and personal lubricants.

"You’ve seen the category size and growth [across these three categories]," he said. "With the trends in America, driven by, whether it’s books [like Fifty Shades of Grey] or things like that, it’s become a mainstream [product]. I actually believe that, and we want to take the brand, it is the mainstream brand, and take it across all the categories and create our next mega-brand."


Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Scimera BioScience launches probiotic to replace ‘good bacteria’ in the gut

BY Michael Johnsen

MIAMI — Scimera BioScience on Thursday announced the launch of a novel probiotic formulation, Asprega ProPac, to address the gastrointestinal side effects of antibiotic therapy including antibiotic-associated diarrhea. Unique to ProPac, Scimera packages its probiotic in a convenient 10-day course.

According to the company, as many as 30% of patients on an antibiotic regimen have gastrointestinal distress or ADD. ProPac, with a complex blend of 11 probiotic strains and saccharomyces boulardii yeast, addresses the "good bacteria" sometimes disturbed during antibiotic therapy.

"We have seen plenty of evidence over the past half-dozen years that probiotics can prevent antibiotic-associated diarrhea for about 50% to 60% of patients who suffer from symptoms," stated Frederick Chaleff, president and CEO of Scimera BioScience. "Now, we can offer patients an affordable option to address the side effects from taking their antibiotics."


Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
HEALTH

Patients oppose OTC-to-Rx switches for pseudoephedrine drugs, survey finds

BY Alaric DeArment

WASHINGTON — Patients around the country "strongly" oppose laws that have been proposed to change popular OTC drugs to prescription-only, according to a new survey.

The survey, conducted online by Harris Interactive on behalf of the Asthma and Allergy Foundation of America, polled 2,020 adults in January who had asthma, allergies, cold, cough or flu in the past 12 months and who had purchased OTC drugs for at least one condition during that time.

Results of the survey found that 62% opposed OTC-to-Rx switches for drugs, with more than 18 million households in the United States depending on OTC drugs containing pseudoephedrine to relieve common symptoms. Lately, some states have sought to make PSE drugs Rx-only in an attempt to combat the manufacture of methamphetamine, for which the drug is a key ingredient.

"The data shows us that patients already deal with the burdens of these chronic diseases, so adding restrictions on top of the burdens they already face would be a real problem," AAFA VP policy and programs Charlotte Collins said. "And they feel the best way to stop criminals involved in the illegal meth trade is through law enforcement and other proven methods, not by doctors’ prescriptions."

The survey also found that 64% of patients say they’re managing medications for two or more people in their households, while patient households deal with allergy symptoms for more than two months per year. One-in-five patients can get in to see a doctor the same day, with 22% having to wait more than a week to get an appointment, and patients say 42% of their visits to the doctor require time off of work, with 31% saying their doctor visits always take place during work hours. Including drive time, time in the waiting room and the visit itself, only one-in-five patients surveyed spend less than an hour when visiting the doctor, with nearly one-third requiring two or more hours per visit, and 9% requiring three or more hours per visit. Fifty-nine percent of patients surveyed spend at least $20 per doctor visit, plus 4-in-5 of them paying to fill prescriptions frequently or occasionally for themselves or family members.

"Patients are really concerned about extreme local laws that limit their freedom to access meds," Collins said. "AAFA is working with patients nationwide to teach lawmakers about better solutions. We want to make sure the patient voice is heard."


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?